speaker
Conference Operator
Operator

Good day and welcome to Elanco Animal Health Report's third quarter 2026 results. At this time, all participants are on listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question, you will need to press star 11 on your touch-tone telephone. Please note, this call may be recorded. I would like to turn the call over to Tiffany Kanaga, Vice President of Investor Relations. Please go ahead.

speaker
Tiffany Kanaga
Vice President, Investor Relations and ESG

Good morning. Thank you for joining us for Elanco Animal Health's third quarter 2026 earnings call. I'm Tiffany Kanaga, Vice President of Investor Relations and ESG. Joining me on today's call are Jeff Simmons, our President and Chief Executive Officer, Bob VanHimbergen, our Chief Financial Officer, and Beth Haney from Investor Relations. The slides referenced during this call are available on the Investor Relations section of elanco.com. Today's discussion will include forward-looking statements. These statements are based on our current assumptions and expectations and are subject to risks and uncertainties that could cause actual results to differ materially from our forecast. For more information, see the risk factors discussed in today's earnings press release as well as in our latest Form 10-K and 10-Q filed with the SEC. We do not undertake any duty to update any forward-looking statements. Our remarks today will focus on our non-GAAP financial measures. Reconciliations of these non-GAAP measures are included in the appendix of today's slides and in the earnings press release. References to organic performance represent revenue growth, excluding the impacts from royalty revenue and sales-based milestones that were sold to a third party, foreign exchange rates, and acquisitions and divestitures. After our prepared remarks, we'll be happy to take your questions. I will now turn the call over to Jeff.

speaker
Jeff Simmons
President and Chief Executive Officer

Thanks, Tiffany. Good morning, everyone. Elanco delivered an outstanding third quarter, outperforming our commitments in growing revenue 11% on a reported basis, or 9%. We are growing the right way, with accelerating price up 4% and volume up 5%, reflecting the value created by our basket of innovation and our diverse portfolio. This translated to significant gross margin expansion up 300 basis points and greater free cash flow, moving our net leverage ratio under the three times milestone. Growth, Innovation, Cash. We are consistently executing along these three priorities, powered by our balanced business profile, strategically built to produce results as industry and competition evolves. And we're just getting started with significant runway for share gains off a small base and large growing global market. As highlighted on slide four, Elanco exceeded the high end of guidance for revenue, adjusted EBITDA, and adjusted EPS. Growth was led by international pet health up 17% and U.S. pet health up 13% with positive contributions from Global Farm Animal. In the third quarter, we saw strong veterinarian and pet owner demand for what we believe is best medicine innovation that we're bringing to the table. Zanrelia once again led Total Elanco growth with Cordelio Cuatro also a major contributor. Both brands achieved record market share in the U.S. in September. Our Big Six, led by Zanrelia and Cuatro, helped drive $328 million of third quarter revenue from innovation, up 40% year over year. We are raising our full-year innovation revenue target to $1.275 billion to reflect continued momentum for our basket of innovation on a stable base. Looking ahead, Elanco has entered into the final quarter of the year with continued momentum from a position of strength. We are meaningfully raising full-year guidance by fully passing through the third quarter B. Moving into 2027, we anticipate building on this year's expected outperformance. We are recommitting to deliver our annual algorithm of mid-single-digit revenue growth, high single-digit adjusted EBITDA growth, and low double-digit adjusted EPS growth, creating sustainable value for our customers and our shareholders. Turning to slide five, we break down the third quarter's 9% underlying organic constant currency revenue growth. HV International, our acquisition which closed April 30th, contributed about a point of growth not included in the organic rate, and it further strengthens our global ruminant position. U.S. Pet Health's 13% increase was led by our vet clinic sales of Quattro and Zenrelia, with good growth in vaccines and pain, and a strong overall price contribution. We are creating value for pet owners and the industry through our truly differentiated portfolio of innovation. Thank you for joining us. Thank you for joining us. Third quarter Seresto sales were partially impacted by retailer inventory drawdown, while year-to-date consumption trends for the brand are slightly positive, smoothing out that dynamic. Senreli and Quattro continue to achieve very robust growth outside the vet clinic. Putting it all together, U.S. Pet Health achieved 13% growth despite retail sales being slightly negative in the quarter. We expect our omni-channel leadership New Distribution Points, and OTC Innovation to provide durable growth next year and beyond, allowing us to reach the one-third of pet owners that don't regularly visit the veterinarian. Moving to International Pet Health, we delivered 17% organic constant currency revenue growth, driven by Zenrelia and ADTAP. Zanrelia is rapidly approaching blockbuster status in international pet health alone, with ample room to grow into key category leadership in the $850 million international derm market. U.S. farm animal increased 7% in the quarter, or 10%, including AHV. Growth was led by cattle with good contributions from beef and dairy. And for the rest of the portfolio, swine was positive, more than offsetting a decline in poultry vaccines. International farm animal grew 1% in organic constant currency or 4%, including HV and FX, also reflecting strength and ruminants with notable demand in LATAM. Poultry and swine were negative in the quarter, but combined for positive year-to-date growth. Regional farm cycles may create incremental quarter-on-quarter volatility ahead, but our expectations for accelerating global protein consumption underpin long-term value for the business. Turning to slide six, we delivered $328 million of innovation revenue in the third quarter, led by continued momentum for our big six in aggregate. We are raising our anticipated innovation contribution for 2026. and we are running ahead of our ambition to double the big six between 2025 and 2028. This accelerated pace of innovation sales reflects a competitive advantage in the marketplace that we expect to sustain. It's built on rapid globalization, medically differentiated products with low market share and large categories, our growing commercial strength, data-driven brand investments that are driving increasing brand loyalty and Differentiated Distribution Partnerships. Let's further discuss the progress of our major innovation products on slide seven, starting with Zenrelia. It's an accelerating success story, well exceeding our expectations across geographies, even as competition increases. The third quarter was Zenrelia's biggest yet in both the U.S. and international, with this special product providing its largest ever contribution to total elanco revenue dollar growth. Efficacy is the clear driver behind Zenrelia's momentum, creating substantial value for veterinarians and pet owners and translating into strong growth and share gains. Market demand drove U.S. sales to more than double in the quarter versus last year. Vet clinic penetration climbed to approximately 19,000 or two-thirds of the total clinic base with steady month-to-month gains even as new competition entered. US Jack market share improved seven points year on year, ending on a record high in September, driven by new users and sticky repeat orders and increased penetration in existing clinics. The average US sales per clinic increased 8% from Q2 to Q3, even with new clinics and a competitive entrant. Summing up the performance in the U.S., yes, this quarter was increasingly competitive, but Zenrelia's momentum is stronger than ever. Our expanded sales team is seeing interest in our differentiated medicine superseding marketplace noise. Our strategy is working, and we don't see that changing. Zenrelia grew even faster internationally than in the U.S. in the third quarter and year to date. Growth has accelerated in Europe, the market with three Jack One products for the longest period. Notably, Zenrelia gained 10 share points in Europe in the first half of 2026, the latest available data. This is five times the competitive entrant, driven by higher customer satisfaction with the product. Zenrelia is now in 48 countries outside the U.S., all without label restrictions. We continue to drive significant share gains across key geographies. For example, Senreli has continued to build on its market-leading position in Brazil and has also achieved over 40% share in Japan. Globally, efficacy remains the differentiator, creating this remarkable performance and long-term growth potential. On to our second DERM innovation, Bofrena. Demand continues to build. We have just opened up access to Bofrena to all customers, so our sales team can sell to every clinic, including large corporate accounts. We expect to fill all outstanding orders by next week and to move Bafrena from a phased launch to a full-scale national launch in the first quarter. Bafrena is already showing what our DERM portfolio can do together. About 20% of clinics which have purchased Bafrena have never used Xenrelia, unlocking a new door for Xenrelia. On supply, we're now making Bufrena continually with more than 30 commercial batches produced. We have finished the manufacturing expansion and process scale up and our larger scale test runs have gone well. Although Bufrena did not materially contribute to Q3's 13% growth in U.S. pet health, we expect it to be a major revenue growth driver in 2027 with the potential to be the single largest contributor to U.S. pet health growth next year. Next, on Cordelio Quattro, we are very pleased with another good quarter of dollar share gains and broad spectrum dispensing sales from the U.S. clinics. Quattro's market share increased nine points in Q3 year over year. We have continued aggressive clinic expansion, reaching about 55% of the U.S. base today, up 15 points since Q1. That's an increase of approximately 4,500 clinics in just two quarters, reflecting strong veterinarian and pet owner demand for the four dimensions of differentiation that make Quattro what we believe is best medicine. Like Xenrelia, Quattro exited the quarter with strength, as September was the largest month of Q3, reaching its highest market share ever. Strategic DTC efforts activated demand into the later months of what we see as becoming a prolonged season. Remember that ticks remain active as long as temperatures are above freezing. Speed of tick kill isn't just a clinical metric, it's a household safety requirement. And Quatro's exceptional speed is resonating strongly with pet owners. Quattro's momentum is carried through the typical seasonality to make this Elanco's largest U.S. pet health product, surpassing Seresto on a trailing four-quarter basis. And we're just getting started with very limited global share compared to the two incumbent franchises exceeding $1 billion each. There is ample room for many years of Cordelio Quattro growth through market expansion, Deeper Clinic Penetration, Market Share Gains Within the Clinic, Research Demonstrating Differentiation, and Global Expansion. There is a significant upside outside the U.S., which we expect to help Credelio Family become our largest global product family ever. So far this year, Quattro has launched in Australia, Canada, and Japan. Yesterday, we received a positive opinion for expansion into the EU, the largest geography in the $800 million international broad spectrum market, which is growing double digits. We expect to launch Crudelio Quattro in Europe in Q1 2027 in time for the season. Turning to AdTab, this market-leading international OTC parasiticide is positioned to be Elanco's next blockbuster. Sales grew more than 40% in the third quarter. AdTab continues to be the fastest growing major brand in the nearly $600 million OTC Ecto category in Europe. Moving to farm animal, Xperia has driven strong cattle portfolio synergies year to date. We anticipate Xperia to continue to grow and lift the broader portfolio with multiple levers from extending days of use, continued adoption, and price. At the same time, we do expect moderating growth rates against challenging comparisons. Lastly, on Bovair, our expectations and trajectory are unchanged from our last update. Year-to-date growth is good, but off a small base, with continued demand from CPG companies that supports relatively consistent cattle numbers. We are investing in long-term initiatives to enhance the product value and demonstrate user flexibility. Moving to slide eight, we provide recent highlights across the three parts of our IPP strategy, innovation, portfolio, and productivity. Let's start with innovation. The commercial success of the Big Six proves that innovation is what drives value and growth in the animal health industry, and we are progressing our next wave portfolio without attrition from the 15 plus projects outlined last December. Our pipeline has significantly greater probability, speed, and value since our December 2025 Investor Day, driving our increased confidence behind the five to six blockbuster potential innovations expected through 2031. Next, portfolio, which provides Elanco's diverse, broad-based growth. Global ruminants is a clear example as our fastest growing species year to date, up 12% on an organic constant currency basis or 17% including HV and FX. Global pet health portfolios also have benefited from recent innovation launches, lifting U.S. pain, vaccines, and therapeutics up double digits and driving the EU, Asia, and LATAM each up double digits. Finally, productivity. Through price mix and Elanco Ascend, we achieved significant gross margin expansion in the third quarter, up 300 basis points. Our strong results and working capital discipline have generated free cash flow, tracking ahead of pace in our three-year algorithm for $1 billion through 2028. It has also allowed us to pay down debt faster than planned with another $216 million in the quarter. At 2.9 times net leverage at the end of Q3, we've accelerated capital allocation flexibility. This is an important milestone representing years of consistent execution along our priorities of growth, innovation, and cash, and it opens up new opportunities to drive meaningful long-term value. With that, I'll pass it to Bob to provide more on our third quarter results, financial guidance, and early considerations for 2027.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API